NCCN VERSION 2 2015

NCCN Guidelines Version 2.2015 Breast Cancer

NCCN Guidelines Index Breast Cancer Table of Contents Discussion

Oncol 2011;37:279-289. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21306860 .

subsequent excision. Am J Clin Pathol 2006;126:310-313. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16891208 . 31. Nagi CS, O'Donnell JE, Tismenetsky M, et al. Lobular neoplasia on core needle biopsy does not require excision. Cancer 2008;112:2152- 2158. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18348299 . 32. Hwang H, Barke LD, Mendelson EB, Susnik B. Atypical lobular hyperplasia and classic lobular carcinoma in situ in core biopsy specimens: routine excision is not necessary. Mod Pathol 2008;21:1208-1216. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18660792 . 33. Elsheikh TM, Silverman JF. Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature. Am J Surg Pathol 2005;29:534-543. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15767810 . 34. Karabakhtsian RG, Johnson R, Sumkin J, Dabbs DJ. The clinical significance of lobular neoplasia on breast core biopsy. Am J Surg Pathol 2007;31:717-723. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17460455 . 35. O'Neil M, Madan R, Tawfik OW, et al. Lobular carcinoma in situ/atypical lobular hyperplasia on breast needle biopsies: does it warrant surgical excisional biopsy? A study of 27 cases. Ann Diagn Pathol 2010;14:251-255. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20637429 . 36. Foster MC, Helvie MA, Gregory NE, et al. Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary? Radiology 2004;231:813-819. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15105449 . 37. Hussain M, Cunnick GH. Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast--a review. Eur J Surg

38. Rendi MH, Dintzis SM, Lehman CD, et al. Lobular in-situ neoplasia on breast core needle biopsy: imaging indication and pathologic extent can identify which patients require excisional biopsy. Ann Surg Oncol 2012;19:914-921. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21861212 . 39. Anderson BO, Calhoun KE, Rosen EL. Evolving concepts in the management of lobular neoplasia. J Natl Compr Canc Netw 2006;4:511-522. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16687097 . 40. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010;102:627-637. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20427430 . 41. Stackievicz R, Paran H, Bernheim J, et al. Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ. Isr Med Assoc J 2010;12:290-295. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20929083 . 42. Zhou W, Jirstrom K, Johansson C, et al. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer 2010;10:653. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21118480 . 43. Lari SA, Kuerer HM. Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. J Cancer 2011;2:232-261. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21552384 . 44. Kuhl CK, Schrading S, Bieling HB, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 2007;370:485-492. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17693177 .

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-69